{
    "clinical_study": {
        "@rank": "68991", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the overall response rate of Trametinib when\n      administered orally to patients with relapsed or refractory multiple myeloma"
        }, 
        "brief_title": "A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The effect of on tumor response will be determined using the International Myeloma Working\n      Group uniform response criteria by analyzing changes in serum and urine values of monoclonal\n      protein immunoglobulin kappa and lambda free light chain and ratio, microglobulin, lactate\n      dehydrogenase, hemoglobin and C-reactive proten."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Been identified as having multiple myeloma with activating NRAS, KRAS or BRAF genetic\n             mutations on CD138+ cells, identified by molecular genetic testing\n\n          -  Have been diagnosed with multiple myeloma by having met all three of the following\n             IMWG criteria:\n\n        a  Clonal bone marrow plasma cells >10% b  Presence of serum and/or urinary M-protein (If\n        no monoclonal protein is detected (non-secretory disease), then >/= 30% monoclonal bone\n        marrow plasma cells and/or a biopsy-proven plasmacytoma required.) c  Evidence of\n        end-organ damage that can be attributed to the underlying plasma cell proliferative\n        disorder, specifically, one or more of the following: (i)  Hypercalcemia:  serum calcium\n        >11.5 mg/100 mL (ii)  Renal insufficiency:  serum creatinine >2 mg/dL (iii)  Anemia:\n        normochromic, normocytic with a hemoglobin value >2 g/100 mL below the lower limit of\n        normal or a hemoglobin value <10 g/100 mL (iv)Bone lesions:  lytic lesions, severe\n        osteopenia, or pathologic fracture.\n\n          -  Have measurable disease defined by the following:\n\n             (i)  Serum M-protein \u22651g/dL or urine M-protein \u2265200 mg/24 hours by protein\n             electrophoresis (ii)  If neither serum nor urine M-protein meet the criteria above,\n             then kappa or lambda serum FLC must be \u226510 mg/dL accompanied by an abnormal kappa to\n             lambda ratio (<0.26 or >1.65) (Serum FLC should only be used for patients without\n             measurable serum or urine M-protein spike.)\n\n          -  Have relapsed or refractory disease after two or more prior multiple myeloma\n             treatment regimens, each of which may have consisted of either single or multiple\n             therapies\n\n          -  Be at least 3 weeks beyond the last multiple myeloma therapy and have recovered from\n             acute toxicities of prior therapies measured by CTCAE Ver 3.0.\n\n          -  Have an Eastern Cooperative Oncology Group performance status of 0 to 2\n\n          -  Have life expectancy of at least 3 months\n\n          -  Be \u226518 years of age and willing to provide written informed consent\n\n          -  For women of childbearing potential, must have used effective contraceptive methods\n             for previous 4 weeks and agree to continue using such methods during the study and\n             for at least 4 months after completing the study, this must include the use of a\n             male/female latex barrier method of contraception (for male participants (See\n             APPENDIX K). TMTB is a pregnancy category D drug. A female of childbearing potential\n             is defined as a female who has not been in natural menopause for the previous,\n             consecutive 24 months, or undergone hysterectomy or bilateral oophortectomy. Women of\n             childbearing potential must have a negative serum pregnancy test within 24 hours\n             before the initiation of TMTB therapy.\n\n          -  Have an absolute neutrophil count >1,000/mm3\n\n          -  Have a platelet count >50,000/mm3\n\n          -  Have total direct bilirubin <2.0 mg/dL\n\n          -  Have aspartate aminotransferase and alanine aminotransferase \u22643 times the upper limit\n             of normal\n\n          -  Have serum creatinine \u22642.5 times the upper limit of normal\n\n          -  Have hemoglobin \u22658.5 g/dL\n\n          -  All prior treatment- related toxicities must be CTCAE (Version 3.0) \u2264 Grade 1 (except\n             alopecia)\n\n          -  Subject is able to swallow and retain orally administered medication and does not\n             have any clinically significant gastrointestinal abnormalities that may alter\n             absorption such as malabsorption syndrome or major resection of the stomach or bowels\n\n        Exclusion Criteria:\n\n          -  Have an active infection or serious comorbid medical condition\n\n          -  Be receiving other concurrent anticancer agents or therapies\n\n          -  Be receiving other concurrent investigational therapies or have received\n             investigational therapies within 3 weeks of screening, not inclusive of molecular\n             genetic testing\n\n          -  Be eligible to receive any other standard therapy available that is known to extend\n             life expectancy\n\n          -  For women be pregnant, nursing, unwilling or unable to utilize two forms of birth\n             control, including the use of a latex condom.\n\n          -  Have a history of another malignancy, except as noted below Exception: Subjects who\n             have been disease-free for 3 years, or subjects with a history of completely resected\n             non-melanoma skin cancer and/or subjects with indolent second malignancies are\n             eligible.\n\n          -  Any serious and/or unstable pre-existing medical disorder (aside from malignancy\n             exception above), psychiatric disorder, or other conditions that could interfere with\n             subject's safety, obtaining informed consent or compliance to the study procedures.\n\n          -  History of interstitial lung disease or pneumonitis.\n\n          -  Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs\n             chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO).\n\n          -  Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity,\n             biologic therapy, or immunotherapy within 21 days prior to randomization and/or daily\n             or weekly chemotherapy without the potential for delayed toxicity within 14 days\n             prior to randomization.\n\n          -  History of  retinal vein occlusion (RVO)\n\n          -  Symptomatic or untreated spinal cord compression.\n\n          -  Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C\n             Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV\n             infection will be permitted).\n\n          -  History or evidence of cardiovascular risk including any of the following (See\n             APPENDIX M for more details):\n\n        a  LVEF<LLN b  A QT interval of \u2265 480 msec corrected for heart rate using the Bazett's\n        formula (QTcB;).\n\n        c  History or evidence of current clinically significant uncontrolled arrhythmias.\n\n        Exception:  Subjects with controlled atrial fibrillation for >30 days prior to study\n        enrollment d  History of acute coronary syndromes (including myocardial infarction and\n        unstable angina), coronary angioplasty, or stenting within 6 months prior to study\n        enrollment\n\n        *  History or evidence of current \u2265 Class II congestive heart failure as defined by New\n        York Heart Association (NYHA).\n\n        a  Treatment refractory hypertension defined as a blood pressure of systolic> 140 mmHg\n        and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy; b\n        Patients with intra-cardiac defibrillators; c  Known cardiac metastases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140840", 
            "org_study_id": "UARK 2014-08"
        }, 
        "intervention": {
            "description": "2 mg of Trametinib daily by mouth in 28 day cycles", 
            "intervention_name": "Trametinib", 
            "intervention_type": "Drug", 
            "other_name": [
                "Mekinist", 
                "TMTB", 
                "JTP-74057", 
                "JTP-78296", 
                "JTP-75303"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "TMTB", 
            "Mekinist", 
            "Trametinib", 
            "relapse", 
            "refractory", 
            "response rate"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "contact": {
                "email": "pettynathanm@uams.edu", 
                "last_name": "Nathan M Petty", 
                "phone": "501-526-6990", 
                "phone_ext": "2435"
            }, 
            "facility": {
                "address": {
                    "city": "Little Rock", 
                    "country": "United States", 
                    "state": "Arkansas", 
                    "zip": "72205"
                }, 
                "name": "University of Arkansas for Medical Sciences"
            }, 
            "investigator": [
                {
                    "last_name": "Aasiya Matin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Aziz Bakhous, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bart Barlogie, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jameel Muzaffar, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yogesh Jethava, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Maurizio Zangari, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Senu Apewokin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Monica Grazziutti, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Xenofon Papanikolaou, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Frits Van Rhee, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Donald Johann, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rashid Khan, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ling Gao, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Shebli Atrash, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib in Patients With Relapsed of Refractory Multiple Myeloma", 
        "overall_contact": {
            "email": "pettynathanm@uams.edu", 
            "last_name": "Nathan M Petty", 
            "phone": "501-526-6990", 
            "phone_ext": "2435"
        }, 
        "overall_contact_backup": {
            "email": "jrtoups@uams.edu", 
            "last_name": "Jennifer R Toups", 
            "phone": "501-526-6990", 
            "phone_ext": "2431"
        }, 
        "overall_official": {
            "affiliation": "University of Arkansas", 
            "last_name": "Christoph Heuck, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The response rate of Trametinib when administered orally to patients with relapsed multiple myeloma", 
            "safety_issue": "No", 
            "time_frame": "28 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140840"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Arkansas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Arkansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}